Response to Corcept’s retraction request on manuscript of “Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study”

Author: Qiaoping XU ¹
Author Information

1. Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Cancer Center, Affiliated Hangzhou First People’s Hospital, Westlake University School of Medicine, Hangzhou, China
Publication Type:Corrigendum
From:Journal of Gynecologic Oncology 2025;36(6):e140-
CountryRepublic of Korea
Language:English